Study finds hydroxychloroquine delays disability for least treatable form of multiple sclerosis
SIRT2: Another important factor that determines the toxic effects and potential mechanisms of particulate matter 2.5
13 January 2022Maternal COVID-19 infection increases risks of preterm birth, low birth weight and stillbirth
13 January 2022Study finds hydroxychloroquine delays disability for least treatable form of multiple sclerosis
A University of Calgary study has found promising results for the generic drug hydroxychloroquine when used to treat the evolution of disability of primary progressive multiple sclerosis (MS), the least treatable form of the autoimmune disease. MS affects about 90,000 Canadians with about 15 percent of those diagnosed with primary progressive MS, one of the highest rates in the world.
